Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii

Antimicrobial Resistance and Infection Control

Elaine Larson¹  Jianfang Liu¹  Bevin Cohen¹  Darcy Ellis² 

[1]School of Nursing, Columbia University Medical Center, 630 West 168th Street, New York 10032, NY, USA

[2]Mailman School of Public Health, Columbia, University Medical Center, 722 West 168th Street, New York 10032, NY, USA

Others  :  1230950
DOI  :  10.1186/s13756-015-0083-2

 received in 2015-07-01, accepted in 2015-10-02,  发布年份 2015

【 摘 要 】

Background

Acinetobacter baumannii can cause serious healthcare-associated infections (HAIs) and the incidence is increasing, with many strains now resistant to multiple antibiotic classes. The aims of this study were to examine factors associated with HAIs caused by antimicrobial-resistant as compared with antimicrobial-susceptible strains of A. baumannii and to investigate trends in the incidence of resistance over time. Electronic data from two U.S. hospitals in a large urban healthcare system in over the years 2006–2012 were used for the analysis. Multiple logistic regression was used to explore risk factors for infection with A. baumannii resistant to ampicillin or ampicillin/sulbactam in the bloodstream, urinary tract, and respiratory tract. The Cochran-Armitage trend test was used to explore resistance trends over time.

Findings

A total of 671 adults with first-time A. baumannii infection were included in the analysis; 302 isolates (45 %) were resistant to ampicillin or ampicillin/sulbactam and 369 (55 %) were susceptible. In the multivariable analysis, significant risk factors included longer length of stay prior to infection (Odds Ratio [OR] = 1.03; 95 % Confidence Interval [CI]: 1.01, 1.04), hospital A versus B (OR = 0.35; 95 % CI: 0.13, 0.93), and antibiotic use prior to infection (OR = 2.88; 95 % CI: 1.02, 8.13). Resistance was more common in respiratory infections (OR = 2.96; 95 % CI: 1.04, 8.44). No trend was found between year of infection and resistance.

Conclusions

The risk factors we identified are consistent with previous findings, but we found no evidence in this population that resistance to ampicillin or ampicillin/sulbactam was increasing over time.

【 授权许可】

   
2015 Ellis et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Maragakis L, Perl T. Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options. Clin Infect Dis. 2008; 46:1254-1263.
• [2]Ozgur ES, Horasan ES, Karaca K, Ersoz G, Nayci Atis S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes. Am J Infect Control. 2014; 42:206-208.
• [3]Marshall C. A longitudinal study of Acinetobacter in three Australian hospitals. J Hosp Infect. 2007; 67:245-252.
• [4]Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA et al.. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infec Control Hosp Epidemiol. 2008; 29:996-1011.
• [5]Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A et al.. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infec Control Hosp Epidemiol. 2013; 34:1-14.
• [6]Cisneros J, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: Epidemiology, clinical features and treatment. Clin Microbiol Infec. 2002; 8:687-693.
• [7]Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: A universal threat to public health. Int J Microbiol Agents. 2008; 32:106-119.
• [8]Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nature Rev Microbiol. 2007; 5:939-951.
• [9]Fournier PE, Richet H. The epidemiology and control of A. baumannii in health care facilities. Healthcare Epidemiology. 2006; 42:692-699.
• [10]Playford E, Craig J, Iredell J. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences. J Hosp Infect. 2007; 65:204-211.
• [11]Zhou H, Yuan Z, Du Y. Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: A systematic review and meta-analysis. Int J Infect Dis. 2014; 22:25-30.
• [12]Villar M, Cano ME, Gato E, Garnacho-Montero J, Miguel Cisneros J et al.. Epidemiologic and Clinical Impact of Acinetobacter baumannii Colonization and Infection. Medicine. 2014; 93:202-210.
• [13]Bergogne-Berezin E, Towner K. Acinetobacter spp. as Nosocomial Pathogens: Microbiological, Clinical, and Epidemiological Features. Clin Microbiol Rev. 1996; 9:148-165.
• [14]Apte M, Neidell M, Furuya EY, Caplan D, Larson E. Using Electronically Available Inpatient Hospital Data for Research. Clin Transl Sci. 2011; 4:338-345.
• [15]Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36:309-332.
• [16]Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis. 1987; 40:373-383.
• [17]Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J et al.. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007; 13:97-103.
• [18]Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK et al.. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis. 2012; 73:267-270.
• [19]Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M et al.. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae in Brooklyn. NY J Antimicrob Chemother. 2007; 60:78-82.
• [20]Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H et al.. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother. 2010; 54:2235-2238.
• [21]Manchanda V, Sanchaita S, Singh NP. Multidrug Resistant Acinetobacter. J Glob Infect Dis. 2010; 2:291-304.
• [22]Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008; 8:752-762.
• [23]Bayuga S, Zeana C, Sahni J, Della-Latta P, El-Sadr W, Larson E. Prevalence and antimicrobial patterns of Acinetobacter baumannii on hands and nares of hospital personnel and patients: The iceberg phenomenon again. Heart Lung. 2002; 31:382-390.
• [24]Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A et al.. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res. 2008; 43:1424-1441.